Skip to Main Content

Update

Your source for campus news

Learn About Advances in Cancer Treatment, Prevention at Bronco Zone Oct. 5

By: Kathleen Tuck   Published 7:41 am / September 28, 2016

Cheryl Jorcyk in her lab.

Cheryl Jorcyk

A panel of Boise State cancer researchers will discuss their research and advances in the field of cancer treatment and prevention at a free presentation at the Bronco Zone from 11:30 a.m.-noon on Wednesday, Oct. 5. The campus community is invited to attend as part of the Buck Cancer week of events.

Lunch also is available for those who would like to stay after the presentation. The Bronco Zone is located on the third floor of the Stueckle Sky Center. Please enter through the north elevator tower to access Bronco Zone. Bronco Zone lunches are offered every Wednesday and Thursday through the academic year.

Check out the menu or reserve your seat online at eventservices.boisestate.edu/broncozone. To enjoy Bronco Zone lunches you must be part of one of the following groups:

  • Alumni Association
  • Boise State University faculty and staff
  • Boise State University faculty and staff emeriti
  • Bronco Athletic Association
  • President’s Club donors
  • Varsity B members

Panel presenters are Ken Cornell, Daniel Fologea, Cheryl Jorcyk and Julie Oxford. Moderator is Greg Hahn, vice president for communications and marketing.

Ken Cornell, associate professor of chemistry

Cornell and colleague Don Warner are working to develop new anti-cancer drugs that have reduced toxic side effects. Most of their work is focused on doxorubicin (DOX) analogs and their use in recurring or metastatic soft tissue sarcoma (STS). STS patients are limited in the number of DOX treatments they can receive (even when it is working) by the increasing risk of cardiotoxicity that accompanies long term therapy. Cornell’s lab studies new non-cardiotoxic analogs using a variety of cell culture and animal models of disease to probe the effectiveness of these drugs in killing cancer cells and reducing tumor growth.

Daniel Fologea, assistant professor of physics

Our research focuses on developing new approaches for controlled drug delivery of anticancer drugs only at the tumor site. In this endeavor, we designed drug carriers capable of releasing their payload when exposed to X-ray radiation conventionally used for radiotherapy.

Cheryl Jorcyk, director of clinical and translational researcher and professor of biological sciences

In recent years, biomedical research at Boise State University has increased dramatically. One of these labs in particular studies one of the most devastating diseases known: Cancer. Jorcyk and members of her lab have worked tirelessly to gain insight into the connection between inflammation and cancer. Previously, the lab has correlated inflammatory proteins with an increased metastatic process in breast, prostate and ovarian cancers. It is currently focused on inhibiting these processes, and migrating towards inflammation in another deadly cancer; carcinoma of the prostate.

Julia Oxford, director of the Biomolecular Research Center and professor of biology

Cancer research in Oxford’s lab focuses on developing new diagnostic tools. Specifically, she and her colleagues have designed specific antibodies that can be used by pathologists as they analyze tissue biopsies from patients.